AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01542814 — intervention group
Intervention type: DEVICE
Intervention: 3Dimensional Mammography
Description: The FUJIFILM 3DM examination is a 4-view mammogram which includes CC and MLO views of each breast. For each view, a routine (0-degree) mammogram will be acquired followed immediately in the same compression by a second mammogram offset at 4 degrees.
Study NCT01542814 — intervention group
Intervention type: DEVICE
Intervention: 2D FFDM
Description: Standard of care screening mammogram.
Study NCT03442218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clorhexidine
Description: Vaginal wash with clorhexidine solution previous to cesarean section in patients with premature rupture of membranes.
Study NCT03442218 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: Vaginal wash with saline solution previous to cesarean section in patients with premature rupture of membranes.
Study NCT05127239 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone Application with lifestyle modification Intervention
Description: The study will introduce a health-promoting lifestyle through the combination of a smartphone app (MyFitnessPal) for the experimental group, emphasizing the use of behavior change techniques to reduce weight, thereby improving the obstructive sleep apnea with overweight and obese employees in the workplace. The self-monitoring, instant feedback, and social support, as well as individualized tailor-made functions are used in intervention programs. The intervention process adopts a healthy weight reduction plan, focusing on a balanced diet, moderately reducing the calories of the food, and combining weight loss methods such as increasing exercise as the main axis, emphasizing the concept of self-monitoring of weight, calorie intake, and exercise .
Study NCT04036942 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ablation of the gastroesophageal junction with hybrid argon plasma
Description: In the management group with argon plasma hybrid after marking 270 degrees of the esophagogastric junction, submucosal elevation and argon plasma burn of the marked and elevated area is performed.
Study NCT04036942 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mucosectomy with band of the gastroesophageal junction
Description: In the management group with mucosectomy after marking 270 degrees of the esophagogastric junction, a submucosal elevation of the marked area is performed to subsequently perform ligation and resection with a hot snare below the ligation area.
Study NCT04296981 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: video-based patient information
Description: explanatory video (8 minutes) concerning communication, stroke issues and stages of the continuum of care
Study NCT01726738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BRAF inhibitor dabrafenib and MEK inhibitor trametinib
Description: Patients will receive the BRAF inhibitor dabrafenib and MEK inhibitor trametinib orally at the RP2D determined in the Phase I/II study (BRF113220): trametinib 2mg QD and dabrafenib 150 mg BID on a continuous basis. A cycle will be defined as 3 weeks in duration. Cycles will be repeated until disease progression (clinical or radiological). Patients may remain on treatment after progression (at the discretion of the investigator) as long as they are still experiencing clinical benefit.
Study NCT02313753 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CLASP
Study NCT02313753 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SAFE
Study NCT02676531 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Walking meditation exercise program
Study NCT03026465 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polymer-free stent
Description: PCI using a polymer-free dual-drug sirolimus- and probucol-eluting stent (Coroflex ISAR)
Study NCT03026465 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biodegradable-polymer stent
Description: PCI using a biodegradable-polymer biolimus-eluting stent (Biomatrix)
Study NCT01280695 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Capsules
Study NCT01280695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSDC-0602 100 mg
Description: MSDC-0602 100 mg Capsules
Study NCT01280695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSDC-0602 250 mg
Description: MSDC-0602 250 mg Capsules
Study NCT01280695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSDC-0602 250 mg
Description: MSDC-0602 500 mg Capsules
Study NCT01280695 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Pioglitazone 45 mg Capsules
Study NCT02900768 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Combination of resistance and aerobic exercises for 100 days.
Study NCT04087577 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional physical therapy
Description: includes electrical stimulation for denervated muscles, and soft tissue massage, joint range of motion exercises to maintain the flexibility of the affected joint, muscle or connected tissues, sensory relearning
Study NCT04087577 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional physical therapy
Description: includes electrical stimulation for denervated muscles, and soft tissue massage, joint range of motion exercises to maintain the flexibility of the affected joint, muscle or connected tissues, sensory relearning
Study NCT04087577 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mirror therapy
Description: mirror therapy
Study NCT02218593 — intervention group
Intervention type: DEVICE
Intervention: WREX orthosis
Description: Upper extremity exoskleton used to assist movement
Study NCT02902393 — intervention group
Intervention type: BIOLOGICAL
Intervention: Thromboelastography
Study NCT02602158 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Octanoic acid (1-13C, 99%)
Description: 13C-marker will be mixed with emulsions. 2 isovolumetric (200 ml) and isocaloric (200 kcal) lipid emulsions with different acid and shear stability Lipid emulsion 1: acid stable, particle size 0.6 µm~Optional study pending interim analysis:~Lipid emulsion 4: acid unstable, redispersible by mechanical processes during antral contractions and passage through the pylorus, particle size 0.6 µm
Study NCT02602158 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: TRIOCTANOIN (1,1,1-13C3, 99%)
Description: 13C-marker will be mixed with emulsions 2 isovolumetric (200 ml) and isocaloric (200 kcal) lipid emulsions with different acid and shear stability~Lipid emulsion 1: acid stable, particle size 0.6 µm~Optional study pending interim analysis:~Lipid emulsion 4: acid unstable, redispersible by mechanical processes during antral contractions and passage through the pylorus, particle size 0.6 µm
Study NCT02315560 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATOR (TENS
Description: electrical stimulation of the nerves in the foot on the incidence of nocturnal enuresis (bedwetting) in children
Study NCT01456312 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Peginterferon alfa-2a
Description: Duration and combination
Study NCT01456312 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Entecavir
Description: combination
Study NCT02650063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-117
Study NCT04079998 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Procellera®
Description: Application of Procellera® dressing.
Study NCT04079998 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Application of standard of care dressings as prescribed.
Study NCT03009617 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: the educational program and counseling
Description: to examine the effectiveness of web-based health education and consultation on health promotion behaviors of adolescents, their e-health literacy, and their information levels.
Study NCT02736916 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: HS-WBRT PCI
Description: LD-SCLC patients with HS-WBRT PCI
Study NCT02736916 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional PCI
Description: LD-SCLC patients with conventional PCI
Study NCT00520910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polypodium leucotomos
Description: Subject is given a 7.5 mg/kg oral dose of Polypodium leucotomos during Baseline visit, and again at 8 hours and 2 hours before the Follow-up visit #2.
Study NCT03620084 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Expiratory Muscle Strength Training (EMST)
Description: The target home practice frequency on the EMST-150 is: 5 repetitions of forceful expiration each time, 5 times daily, 5 days a week for 8 weeks, following the training protocol used by Hutcheson et al. (2017).
Study NCT02736435 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Guided High Intensity Focused Ultrasound
Description: Direct treatment of uterine fibroids with MR-HIFU
Study NCT01403324 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: TSH stimulation
Description: rh TSH stimulation followed by thyroid hormon withdrawal
Study NCT01884675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambrisentan 5 mg
Description: White, film-coated, immediate-release tablets, containing 5 mg ambrisentan for single dose oral.
Study NCT01884675 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: White, film-coated, ambrisentan-matching placebo tablet for single oral dose
Study NCT00218439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine
Description: 10 mg for 1 week followed by 20 mg for 3 weeks
Study NCT02009722 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Duramorph is administered as part of spinal anesthesia for post-operative pain relief.
Study NCT02009722 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone
Description: Hydromorphone (Dilaudid) is administered in the intrathecal space for post-operative pain control
Study NCT01494259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Up to 300cc of 0.5% bupivacaine administered to the mastectomy site via 2 catheters connected to the Symbios GOPump at a rate of 2 cc per hour per catheter over 3 days.
Study NCT01494259 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Up to 300cc of normal saline administered to the mastectomy site via 2 catheters connected to the Symbios GOPump at a rate of 2 cc per hour per catheter over 3 days.
Study NCT02794727 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Blinded Fitbit
Description: Subjects will wear a blinded Fitbit to monitor activity while in the workplace for 12 weeks.
Study NCT01076504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amrubicin
Description: 30 mg/m2 IV on Days 1-3 of each 3-week treatment cycle
Study NCT00218439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT03297463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2 & Ipilimumab (P-Ib)
Description: Phase Ib:~- Ipilimumab will be administered in a 3 + 3 dose escalation design.~* The starting dose will be 0.3 mg/kg administered within 7 days of day 1 cycle 2 ALdesleukin (IL-2).~* If dose limiting autoimmune toxicities (DLTs) are not observed, the next cohort will receive 1.5 mg/kg.~* The final cohort will receive 3 mg/kg, in the event that cohort 2 does not exhibit DLTs.~* In the event of excessive toxicity in cohort 1, then a -1 dose level of 0.1 mg/kg may be evaluated in subsequent cohorts. Cohort sizes will increase to 6 patients if 1 of 3 patients in a cohort experience a DLT.~* Once the maximum tolerated dose/recommended phase 2 dose (MTD/RP2D) is declared, no staggering of enrollment is required for accrual.
Study NCT03297463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2 & Ipilimumab (P-II)
Description: Phase II:~- Interleukin-2 \& Ipilimumab will be administered at the maximum tolerated dose/recommended phase 2 dose (MTD/RP2D).
Study NCT01076504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC=5 IV, Day 1 of each 3-week treatment cycle
Study NCT01076504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: 6 mg SQ on Day 4 of each 3 week treatment cycle
Study NCT00915512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone extended-release (ER)
Description: Paliperidone ER tablets will be administered orally once daily as flexible dose ranging from 3 to 12 milligram (mg) per day for 12 months. The recommended dose will be 6 mg once daily.
Study NCT03691831 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active
Description: A-101 45% (hydrogen peroxide 45% topical solution)
Study NCT03691831 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle solution containing isopropyl alcohol and water
Study NCT00542321 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual turn
Description: Manual turn from side to back to side every 2 hours by nurses while patient receiving mechanical ventilation
Study NCT00542321 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: kinetic therapy bed
Description: Continuous, automated turning to a maximum of 45 degrees in the lateral positions while the patient is receiving mechanical ventilation
Study NCT03260543 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fermented ginseng powder
Description: tablets (2 tablets/day, 125 mg \& 500 mg/day) for 12 weeks.
Study NCT03260543 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 12 weeks.
Study NCT02502591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pudendal Nerve Block
Description: An injection of local anaesthetic (3 ml of 0.25% bupivacaine) will be administered around the trunk of the pudendal nerve.
Study NCT02101866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vapendavir 300 mg tablet
Description: tablet - single dose
Study NCT02101866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vapendavir 132 mg capsules
Description: 2 capsules - single dose
Study NCT03581708 — intervention group
Intervention type: OTHER
Intervention: lung cancer
Description: If the patient is diagnosed with lung cancer in advanced stage, he/she will be followed up for VTE incidence
Study NCT02794727 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Unblinded Fitbit
Description: Subjects will be unblinded to the Fitbit display for 12 weeks with set activity goals.
Study NCT00547586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-methylnaltrexone bromide (MOA-728)
Description: Oral
Study NCT00547586 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT02736435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leuprolide acetate for depot suspension
Description: Treatment of uterine fibroids with leuprolide acetate prior to MR-HIFU
Study NCT01248741 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: HDR prostate brachytherapy
Description: HDR prostate brachytherapy to be delivered in 2 fractions of 10 Gray as a boost combined with external beam radiotherapy
Study NCT03043391 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Polio/Rhinovirus Recombinant (PVSRIPO)
Description: PVSRIPO will be delivered intratumorally by convection-enhanced delivery (CED) using an intracerebral catheter placed within the enhancing portion of the tumor. A stereotactic biopsy will be performed prior to virus administration. Immediately following the stereotactically-guided tumor biopsy, a catheter will be implanted in the operating room at a site the same or different from that used for the biopsy using sterile techniques under general anesthesia. The entire volume of PVSRIPO to be delivered will be pre-loaded into a syringe by the investigational pharmacist and connected to the catheter under sterile conditions in the Pediatric Intensive Care Unit (PICU) just prior to beginning of infusion.
Study NCT04382248 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smartphone App
Description: An app for monitoring medications, blood pressure, exercise, healthy eating
Study NCT04382248 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smartphone App
Description: An app for monitoring medications, blood pressure, exercise, healthy eating
Study NCT04382248 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored education
Description: in-person coaching
Study NCT03571919 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine infusion
Description: Intravenous bolus of lidocaine (1.25 mg/kg) and then infusion at 1 mg/kg/hr
Study NCT03571919 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline infusion
Description: Intravenous bolus of saline and then infusion
Study NCT04518007 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: hyperbaric oxygen therapy
Description: The HBOT protocol consists of 60 daily sessions, five times per week, each session lasting 90 minutes.~Investigational product:~Multiplace hyperbaric oxygen chamber (Haux, Germany) located at the Sago l Center for Hyperbaric Medicine and Research, Shamir (Assaf-Harofeh) Medical Center, Israel.
Study NCT04518007 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: hyperbaric oxygen therapy
Description: The HBOT protocol consists of 60 daily sessions, five times per week, each session lasting 90 minutes.~Investigational product:~Multiplace hyperbaric oxygen chamber (Haux, Germany) located at the Sago l Center for Hyperbaric Medicine and Research, Shamir (Assaf-Harofeh) Medical Center, Israel.
Study NCT04431791 — intervention group
Intervention type: DRUG
Intervention: Regorafenib
Description: oral regorafenib
Study NCT04431791 — intervention group
Intervention type: DRUG
Intervention: Fruquintinib
Description: oral fruquintinib
Study NCT01930292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part A: Debio 1143
Description: Adaptive doses of Debio1143 oral capsules, between 50 and 400 mg until the recommended dose (RD) is determined.
Study NCT01930292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel standard of care, intravenous (IV), once on day 1 or 2 of each 21-day treatment cycle, after pre-medication to prevent severe hypersensitivity reactions.
Study NCT01930292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin standard of care, intravenous (IV), once on day 1 or 2 of each 21-day treatment cycle.
Study NCT01930292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part B: Debio 1143
Description: RD of Debio1143 oral capsules, once daily for five consecutive days starting on day 1 or 2 of each 21-day treatment cycle.
Study NCT00563238 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol
Description: Metoprolol administered intravenously in 2.5mg boluses until the resting heart rate falls by 10% from baseline to a maximum dose of 10mg, or until there is any apparent adverse reaction.
Study NCT00249470 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Abstinence & Work
Description: Participants in the Abstinence \& Work group were invited to attend the workplace throughout a 26-week intervention period, but were required to provide urine samples that indicated recent cocaine abstinence to gain access to the workplace and to maintain the maximum base pay of $8.00 per hour.
Study NCT00249470 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Work Only
Description: Work Only participants were invited to attend the workplace throughout a 26-week intervention period. Participants in this group continued to provide mandatory urine samples and could earn base and performance pay. Work Only participants could work and earn base and performance pay independent of urinalysis results.
Study NCT00684606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin IV
Description: 5 miu/1000ml Glu/Saline
Study NCT04116645 — intervention group
Intervention type: OTHER
Intervention: genital and rectal swab
Description: 6. Swabs for GBS culture should be obtained, ideally before digital examination or use of lubricants, from both the lower vagina (vaginal introitus) and rectum (insert swab through the anal sphincter) to achieve maximum sensitivity. Either two swabs (one for each site) or a single swab can be used; one swab is more cost saving. The swabs will be obtained by the patient herself after appropriate instruction or by the provider healthcare, as studies have shown equivalent sensitivity between the healthcare provider and the patient herself.
Study NCT00684853 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Description: 1.25 mg of bevacizumab intravitreal
Study NCT00684853 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vetaporfin
Description: full fluence of vetaporfin
Study NCT01637350 — intervention group
Intervention type: PROCEDURE
Intervention: digestive tract reconstruction
Description: Subtotal gastrectomy with BillrothⅠ or BillrothⅡ, total gastrectomy with jejunal interposition or Roux-en-Y reconstruction
Study NCT02152410 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Acupuncture will be applied according to the standards for reporting interventions in clinical trials of acupuncture (STRICTA)